Congress presentations...
 

​​

  • E. Kovacs, D. Stucki and P. Tschumi

    The DNA-repair synthesis in healthy daughters of breast cancer patients. ECCO-3, Stockholm (1985).
     

  • E. Kovacs and D. Stucki

    Impaired DNA-repair synthesis in lymphocytes of breast cancer patients. ECCO-3, Stockholm (1985).
     

  • E. Kovacs, A. Almendral and H. Ludwig

    Deficiency in the DNA-repair synthesis:Is it hereditary or acquired?  ECCO-4, Madrid (1987).
     

  • E. Kovacs, A. Almendral and H. Ludwig

    Does chemo/radiotherapy affect the DNA-repair? First International Congress on management of metastatic disease. Lyon/France (1988).
     

  • E. Kovacs and A. Almendral

    Characterisation of DNA-repair in cancer patients. ECCO-5, London (1989).
     

  • E Kovacs

    Improvement of DNA-repair in breast cancer patients during therapy. ECCO-5, London (1989).
     

  • E. Kovacs

    DNA-repair and carcinogenesis. 15th International Cancer Congress, Hamburg (1990).
     

  • M. Meichsner, E. Kovacs and H. Ludwig

    lnterleukin-2 Rezeptoren in der Dezidua. 48. Kongress der Deutschen Gesellschaft für Gynäkologie & Geburtshilfe, Hamburg (1990).
     

  • T. Hajto, K. Hostanska and E. Kovacs

    Does mistletoe extracts possess the immunomodulatory potency without optimised lectin activity? 4th International Congress on Phytotherapy, Munich (1992).
     

  • E. Kovacs and H. Ludwig

    Relationship of the DNA repair to clinical state in cancer patients. Deutscher Krebskongress, Berlin (1992).
     

  • E. Kovacs

    The effect of Interferon-alpha treatment on the DNA-repair in cancer patients having chemotherapy. 1st Baltic Congress of Oncology and Radiology, Tallin (1994).
     

  • E. Kovacs, JJ. Kuehn, M. Werner and J. Hoffmann

    Effect of lscador® on DNA repair after radiation or cyclophosphamide. Correlation with IFN-gamma production. Gemeinsame Jahrestagung der Deutschen und der Oesterreichischen Gesellschaft für Hämatologie und Onkologie, Hamburg. Onkologie Supplement 2, Vol 18 (1995). 
     

  • E. Kovacs, JJ. Kuehn, M. Werner and J. Hoffmann

    Effect of Iscador treatment on DNA repair in cancer patients. Correlation with immunological parameters. Annual Congress of the German and the Austrian Society of Hematology and Oncology, Düsseldorf. Annals of Hematology Supplement II, Vol 73 (1996).
     

  • E. Kovacs, JJ. Kuehn, M. Werner and J. Hoffmann

    Die Wirkung einer Behandlung mit Viscum album extrakt (Iscador) auf die DNA-Reparatur der Lymphozyten bei Karzinompatienten. Forschende Komplementärmedizin 

    Supplement 1, Vol 3 (1998).
     

  • E. Kovacs

    Serum levels of IL-12, IL-6 and the production of IFN-gamma, IL-2, IL-4 by peripheral blood mononuclear cell in cancer patients treated with Viscum album extract. 10th International AEK Congress, Heidelberg. J Cancer Research and Clinical Oncology Supplement 1, Vol 125 (1999).
     

  • E. Kovacs

    Serum levels of IL-6, slL-6 receptor and sgp130 in cancer patients. 3rd International Dresden Symposium on Immunotherapy of Cancer, Dresden (2000).
     

  • E. Kovacs

    Investigation of IL-6, IL-12, IFN-gamma, IL-16 and IL-4 in serum of cancer patients treated with Viscum album extract (lscador®). 3rd International Congress on Phytomedicine, Munich. Phytomedicine, Supplement II, Vol 7 (2000).
     

  • E. Kovacs

    Beneficial effects of Viscum album (VA) extract therapy in cancer patients. Relation with interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130). 

    12th international AEK congress, Würzburg (2003).
     

  • E. Kovacs 

    Mistletoe (Viscum album) extract or Vincristine? A com-parative study. International Congress on Complementary Medicine Research, Munich, (2007).
     

  • E. Kovacs, S. Link and U. Toffol-Schmidt

    The effect of Viscum album extract and Vincristine on the proliferation in several multiple myeloma cell lines. The function of IL-6 and IL-10 in the proliferation. 4th Mistletoe Symposium, Nonnweiler-Oetzenhausen.  Phytomedicine Supplement VII (2007).
     

  • E. Kovacs

    Can IL-6 inhibit the proliferation of human multiple myeloma cell lines? Is IL-6 a pro-apoptotic factor in these cell lines? American Association for Cancer Research, Tumor Immunology: New Perspectives. Miami (2008).
     

  • E. Kovacs 

    Multiple myeloma: Combination therapy with Interleukin-6 antibody and Interleukin-6 receptor antibody. 1st International Congress for Controversies in Hematology, 

    Rome (2010).
     

  • E. Kovacs-Benke
    The role of cytokines IL-6, IL-10 and TNF-alpha in the pathogenesis of multiple myeloma. Clinical significance. Therapeutic modalities. Oral presentation at the 1st Annual International Symposium of Hematology, Beijing, China (2012).
     

  • E. Kovacs-Benke

    Combination of Interleukin-6 Antibody and Interleukin-6 Receptor Antibody in the Therapy of Multiple Myeloma. ESH International Conference on MULTIPLE MYELOM, Dublin, Ireland (2013).
     

  • E. Kovacs, D. Stucki and P. Tschumi

    The DNA-repair synthesis in healthy daughters of breast cancer patients. ECCO-3, Stockholm (1985).
     

 

  • E. Kovacs-Benke

    Monitoring of Interleukin-6, Interleukin-10 and Tumour Necrosis Factor-alpha, as proliferative factors in Multiple Myeloma. European Myeloma Network Meeting, Turin (2018)
     

  • E. Kovacs-Benke

    Cytokine-Mapping in Colorectal-Cancer. Therapeutic intervention, 13th European Colorectal Congress of St.Gallen, 01-05.12.2019

 

  • E. Kovacs-Benke

    Monitoring and Mapping of the Systemic Lupus Erythematosus, 12th European Lupus Meeting, 25-27 March 2020 in Bruges, Belgium